-
Nov 2021
Autoreactive T cell receptors with shared germline-like α chains in type 1 diabetes.
JCI InsightLinsley PS, Barahmand-Pour-Whitman F, Balmas E, DeBerg HA, Flynn KJ, Hu AK, Rosasco MG, Chen J, O'Rourke C, Serti E, Gersuk VH, Motwani K, Seay HR, Brusko TM, Kwok WW, Speake C, Greenbaum CJ, Nepom GT, Cerosaletti K -
Aug 2021
The Cyclin-Dependent Kinase 8 (CDK8) Inhibitor DCA Promotes a Tolerogenic Chemical Immunophenotype in CD4+ T Cells via a Novel CDK8-GATA3-FOXP3 Pathway.
Mol Cell BiolArnett A, Moo KG, Flynn KJ, Sundberg TB, Johannessen L, Shamji AF, Gray NS, Decker T, Zheng Y, Gersuk VH, Rahman ZS, Levy DE, Marié IJ, Linsley PS, Xavier RJ, Khor B -
Apr 2021
Uncovering Pathways to Personalized Therapies in Type 1 Diabetes.
DiabetesLinsley PS, Greenbaum CJ, Nepom GT -
Feb 2021
Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.
JCI InsightDiggins KE, Serti E, Muir V, Rosasco M, Lu T, Balmas E, Nepom GT, Long SA, Linsley PS -
Aug 2020
Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes.
DiabetologiaRodrigues KB, Dufort MJ, Llibre A, Speake C, Rahman MJ, Bondet V, Quiel J, Linsley PS, Greenbaum CJ, Duffy D, Tarbell KV -
Jan 2020
IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE.
JCI InsightLi D, Matta B, Song S, Nelson V, Diggins K, Simpfendorfer KR, Gregersen PK, Linsley PS, Barnes BJ -
Jan 2020
Inflammatory Cytokines Induce Sustained CTLA-4 Cell Surface Expression on Human MAIT Cells.
ImmunohorizonsBerkson JD, Slichter CK, DeBerg HA, Delaney MA, Woodward-Davis AS, Maurice NJ, Lwo Y, Ko A, Hsu J, Chiu YW, Linsley PS, Dixon D, Prlic M -
Jan 2020
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy.
Nat CommunSheih A, Voillet V, Hanafi LA, DeBerg HA, Yajima M, Hawkins R, Gersuk V, Riddell SR, Maloney DG, Wohlfahrt ME, Pande D, Enstrom MR, Kiem HP, Adair JE, Gottardo R, Linsley PS, Turtle CJ -
Jan 2020
Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression.
J Clin InvestWiedeman AE, Muir VS, Rosasco MG, DeBerg HA, Presnell S, Haas B, Dufort MJ, Speake C, Greenbaum CJ, Serti E, Nepom GT, Blahnik G, Kus AM, James EA, Linsley PS, Long SA -
Dec 2019
A composite immune signature parallels disease progression across T1D subjects.
JCI InsightSpeake C, Skinner SO, Berel D, Whalen E, Dufort MJ, Young WC, Odegard JM, Pesenacker AM, Gorus FK, James EA, Levings MK, Linsley PS, Akirav EM, Pugliese A, Hessner MJ, Nepom GT, Gottardo R, Long SA -
Dec 2019
The human tissue-resident CCR5+ T cell compartment maintains protective and functional properties during inflammation.
Sci Transl MedWoodward Davis AS, Roozen HN, Dufort MJ, DeBerg HA, Delaney MA, Mair F, Erickson JR, Slichter CK, Berkson JD, Klock AM, Mack M, Lwo Y, Ko A, Brand RM, McGowan I, Linsley PS, Dixon DR, Prlic M -
Aug 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
N Engl J MedHerold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. -
Aug 2019
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D.
Curr Opin Endocrinol Diabetes ObesLinsley PS, Long SA -
Apr 2019
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
DiabetologiaPerdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC, Immune Tolerance Network. -
Apr 2019
Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.
Genes ImmunLinsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ
